Question to the Department of Health and Social Care:

To ask Her Majesty's Government, further to the reply by Lord O'Shaughnessy on 7 June (HL Deb, col 1405), what was the outcome of his meeting with patients' groups regarding the use of Ibrutinib in England.

On 22 May I met with the Chronic Lymphocytic Leukaemia Association, and Lord Forsyth regarding the use of ibrutinib in England. Following this meeting, I met with NHS England and the National Institute of Health and Care Excellence to discuss the treatment criteria set by NHS England for ibrutinib. As a result, NHS England committed to receiving, and reviewing by the end of July, any further evidence that patients and clinicians wish to submit on this matter and will review the criteria in light of all evidence submitted.